Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Malaria Journal
Published in: Malaria Journal 1/2018

Open Access 01-12-2018 | Research

Screening for potential prophylactics targeting sporozoite motility through the skin

Authors: Ross G. Douglas, Miriam Reinig, Matthew Neale, Friedrich Frischknecht

Published in: Malaria Journal | Issue 1/2018

Login to get access

Abstract

Background

Anti-malarial compounds have not yet been identified that target the first obligatory step of infection in humans: the migration of Plasmodium sporozoites in the host dermis. This movement is essential to find and invade a blood vessel in order to be passively transported to the liver. Here, an imaging screening pipeline was established to screen for compounds capable of inhibiting extracellular sporozoites.

Methods

Sporozoites expressing the green fluorescent protein were isolated from infected Anopheles mosquitoes, incubated with compounds from two libraries (MMV Malaria Box and a FDA-approved library) and imaged. Effects on in vitro motility or morphology were scored. In vivo efficacy of a candidate drug was investigated by treating mice ears with a gel prior to infectious mosquito bites. Motility was analysed by in vivo imaging and the progress of infection was monitored by daily blood smears.

Results

Several compounds had a pronounced effect on in vitro sporozoite gliding or morphology. Notably, monensin sodium potently affected sporozoite movement while gramicidin S resulted in rounding up of sporozoites. However, pre-treatment of mice with a topical gel containing gramicidin did not reduce sporozoite motility and infection.

Conclusions

This approach shows that it is possible to screen libraries for inhibitors of sporozoite motility and highlighted the paucity of compounds in currently available libraries that inhibit this initial step of a malaria infection. Screening of diverse libraries is suggested to identify more compounds that could serve as leads in developing ‘skin-based’ malaria prophylactics. Further, strategies need to be developed that will allow compounds to effectively penetrate the dermis and thereby prevent exit of sporozoites from the skin.
Appendix
Available only for authorised users
Literature
1.
2.
3.
4.
Flannery EL, Chatterjee AK, Winzeler EA. Antimalarial drug discovery—approaches and progress towards new medicines. Nat Rev Microbiol. 2013;11:849–62.CrossRefPubMedPubMedCentral
5.
Burrows JN, van Huijsduijnen RH, Mohrle JJ, Oeuvray C, Wells TN. Designing the next generation of medicines for malaria control and eradication. Malar J. 2013;12:187.CrossRefPubMedPubMedCentral
6.
Burrows JN, Duparc S, Gutteridge WE, Hooft van Huijsduijnen R, Kaszubska W, Macintyre F, et al. New developments in anti-malarial target candidate and product profiles. Malar J. 2017;16:26.CrossRefPubMedPubMedCentral
7.
Katsuno K, Burrows JN, Duncan K, Hooft van Huijsduijnen R, Kaneko T, Kita K, et al. Hit and lead criteria in drug discovery for infectious diseases of the developing world. Nat Rev Drug Discov. 2015;14:751–8.CrossRefPubMed
8.
da Cruz FP, Martin C, Buchholz K, Lafuente-Monasterio MJ, Rodrigues T, Sonnichsen B, et al. Drug screen targeted at Plasmodium liver stages identifies a potent multistage antimalarial drug. J Infect Dis. 2012;205:1278–86.CrossRefPubMedPubMedCentral
9.
Van Voorhis WC, Adams JH, Adelfio R, Ahyong V, Akabas MH, Alano P, et al. Open source drug discovery with the Malaria Box compound collection for neglected diseases and beyond. PLoS Pathog. 2016;12:e1005763.CrossRefPubMedPubMedCentral
10.
Spangenberg T, Burrows JN, Kowalczyk P, McDonald S, Wells TN, Willis P. The open access malaria box: a drug discovery catalyst for neglected diseases. PLoS ONE. 2013;8:e62906.CrossRefPubMedPubMedCentral
11.
Lucumi E, Darling C, Jo H, Napper AD, Chandramohanadas R, Fisher N, et al. Discovery of potent small-molecule inhibitors of multidrug-resistant Plasmodium falciparum using a novel miniaturized high-throughput luciferase-based assay. Antimicrob Agents Chemother. 2010;54:3597–604.CrossRefPubMedPubMedCentral
12.
Plouffe D, Brinker A, McNamara C, Henson K, Kato N, Kuhen K, et al. In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. Proc Natl Acad Sci USA. 2008;105:9059–64.CrossRefPubMed
13.
Plouffe DM, Wree M, Du AY, Meister S, Li F, Patra K, et al. High-throughput assay and discovery of small molecules that interrupt malaria transmission. Cell Host Microbe. 2016;19:114–26.CrossRefPubMedPubMedCentral
14.
Gamo FJ, Sanz LM, Vidal J, de Cozar C, Alvarez E, Lavandera JL, et al. Thousands of chemical starting points for antimalarial lead identification. Nature. 2010;465:305–10.CrossRefPubMed
15.
16.
Ekland EH, Schneider J, Fidock DA. Identifying apicoplast-targeting antimalarials using high-throughput compatible approaches. FASEB J. 2011;25:3583–93.CrossRefPubMedPubMedCentral
17.
Gego A, Silvie O, Franetich JF, Farhati K, Hannoun L, Luty AJ, et al. New approach for high-throughput screening of drug activity on Plasmodium liver stages. Antimicrob Agents Chemother. 2006;50:1586–9.CrossRefPubMedPubMedCentral
18.
Meister S, Plouffe DM, Kuhen KL, Bonamy GM, Wu T, Barnes SW, et al. Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. Science. 2011;334:1372–7.CrossRefPubMedPubMedCentral
19.
Derbyshire ER, Prudencio M, Mota MM, Clardy J. Liver-stage malaria parasites vulnerable to diverse chemical scaffolds. Proc Natl Acad Sci USA. 2012;109:8511–6.CrossRefPubMed
20.
Avery VM, Bashyam S, Burrows JN, Duffy S, Papadatos G, Puthukkuti S, et al. Screening and hit evaluation of a chemical library against blood-stage Plasmodium falciparum. Malar J. 2014;13:190.CrossRefPubMedPubMedCentral
21.
Vos MW, Stone WJ, Koolen KM, van Gemert GJ, van Schaijk B, Leroy D, et al. A semi-automated luminescence based standard membrane feeding assay identifies novel small molecules that inhibit transmission of malaria parasites by mosquitoes. Sci Rep. 2015;5:18704.CrossRefPubMedPubMedCentral
22.
Baragana B, Hallyburton I, Lee MC, Norcross NR, Grimaldi R, Otto TD, et al. A novel multiple-stage antimalarial agent that inhibits protein synthesis. Nature. 2015;522:315–20.CrossRefPubMedPubMedCentral
23.
Lucantoni L, Silvestrini F, Signore M, Siciliano G, Eldering M, Dechering KJ, et al. A simple and predictive phenotypic high content imaging assay for Plasmodium falciparum mature gametocytes to identify malaria transmission blocking compounds. Sci Rep. 2015;5:16414.CrossRefPubMedPubMedCentral
24.
25.
Chirawurah JD, Ansah F, Nyarko PB, Duodu S, Aniweh Y, Awandare GA. Antimalarial activity of Malaria Box compounds against Plasmodium falciparum clinical isolates. Int J Parasitol Drugs Drug Resist. 2017;7:399–406.CrossRefPubMedPubMedCentral
26.
Raphemot R, Lafuente-Monasterio MJ, Gamo-Benito FJ, Clardy J, Derbyshire ER. Discovery of dual-stage malaria inhibitors with new targets. Antimicrob Agents Chemother. 2015;60:1430–7.CrossRefPubMed
27.
Derbyshire ER, Min J, Guiguemde WA, Clark JA, Connelly MC, Magalhaes AD, et al. Dihydroquinazolinone inhibitors of proliferation of blood and liver stage malaria parasites. Antimicrob Agents Chemother. 2014;58:1516–22.CrossRefPubMedPubMedCentral
28.
Douglas RG, Amino R, Sinnis P, Frischknecht F. Active migration and passive transport of malaria parasites. Trends Parasitol. 2015;31:357–62.CrossRefPubMed
29.
Sidjanski S, Vanderberg JP. Delayed migration of Plasmodium sporozoites from the mosquito bite site to the blood. Am J Trop Med Hyg. 1997;57:426–9.CrossRefPubMed
30.
Amino R, Thiberge S, Martin B, Celli S, Shorte S, Frischknecht F, Menard R. Quantitative imaging of Plasmodium transmission from mosquito to mammal. Nat Med. 2006;12:220–4.CrossRefPubMed
31.
Hellmann JK, Munter S, Wink M, Frischknecht F. Synergistic and additive effects of epigallocatechin gallate and digitonin on Plasmodium sporozoite survival and motility. PLoS ONE. 2010;5:e8682.CrossRefPubMedPubMedCentral
32.
33.
34.
Sultan AA, Thathy V, Frevert U, Robson KJ, Crisanti A, Nussenzweig V, et al. TRAP is necessary for gliding motility and infectivity of Plasmodium sporozoites. Cell. 1997;90:511–22.CrossRefPubMed
35.
Kariu T, Yuda M, Yano K, Chinzei Y. MAEBL is essential for malarial sporozoite infection of the mosquito salivary gland. J Exp Med. 2002;195:1317–23.CrossRefPubMedPubMedCentral
36.
Ejigiri I, Ragheb DR, Pino P, Coppi A, Bennett BL, Soldati-Favre D, et al. Shedding of TRAP by a rhomboid protease from the malaria sporozoite surface is essential for gliding motility and sporozoite infectivity. PLoS Pathog. 2012;8:e1002725.CrossRefPubMedPubMedCentral
37.
Matsuoka H, Yoshida S, Hirai M, Ishii A. A rodent malaria, Plasmodium berghei, is experimentally transmitted to mice by merely probing of infective mosquito, Anopheles stephensi. Parasitol Int. 2002;51:17–23.CrossRefPubMed
38.
Medica DL, Sinnis P. Quantitative dynamics of Plasmodium yoelii sporozoite transmission by infected anopheline mosquitoes. Infect Immun. 2005;73:4363–9.CrossRefPubMedPubMedCentral
39.
Frischknecht F, Baldacci P, Martin B, Zimmer C, Thiberge S, Olivo-Marin JC, et al. Imaging movement of malaria parasites during transmission by Anopheles mosquitoes. Cell Microbiol. 2004;6:687–94.CrossRefPubMed
40.
41.
42.
Vanderberg JP, Frevert U. Intravital microscopy demonstrating antibody-mediated immobilisation of Plasmodium berghei sporozoites injected into skin by mosquitoes. Int J Parasitol. 2004;34:991–6.CrossRefPubMed
43.
Frevert U, Engelmann S, Zougbede S, Stange J, Ng B, Matuschewski K, Liebes L, Yee H. Intravital observation of Plasmodium berghei sporozoite infection of the liver. PLoS Biol. 2005;3:e192.CrossRefPubMedPubMedCentral
44.
Tavares J, Formaglio P, Thiberge S, Mordelet E, Van Rooijen N, Medvinsky A, et al. Role of host cell traversal by the malaria sporozoite during liver infection. J Exp Med. 2013;210:905–15.CrossRefPubMedPubMedCentral
45.
Hopp CS, Chiou K, Ragheb DR, Salman A, Khan SM, Liu AJ, Sinnis P. Longitudinal analysis of Plasmodium sporozoite motility in the dermis reveals component of blood vessel recognition. Elife. 2015;4:e07789.CrossRefPubMedCentral
46.
47.
Sinnis P, Zavala F. The skin stage of malaria infection: biology and relevance to the malaria vaccine effort. Future Microbiol. 2008;3:275–8.CrossRefPubMed
48.
49.
Stewart MJ, Nawrot RJ, Schulman S, Vanderberg JP. Plasmodium berghei sporozoite invasion is blocked in vitro by sporozoite-immobilizing antibodies. Infect Immun. 1986;51:859–64.PubMedPubMedCentral
50.
Hegge S, Kudryashev M, Smith A, Frischknecht F. Automated classification of Plasmodium sporozoite movement patterns reveals a shift towards productive motility during salivary gland infection. Biotechnol J. 2009;4:903–13.CrossRefPubMed
51.
Hellmann JK, Munter S, Kudryashev M, Schulz S, Heiss K, Muller AK, et al. Environmental constraints guide migration of malaria parasites during transmission. PLoS Pathog. 2011;7:e1002080.CrossRefPubMedPubMedCentral
52.
Munter S, Sabass B, Selhuber-Unkel C, Kudryashev M, Hegge S, Engel U, et al. Plasmodium sporozoite motility is modulated by the turnover of discrete adhesion sites. Cell Host Microbe. 2009;6:551–62.CrossRefPubMed
53.
Hegge S, Munter S, Steinbuchel M, Heiss K, Engel U, Matuschewski K, et al. Multistep adhesion of Plasmodium sporozoites. FASEB J. 2010;24:2222–34.CrossRefPubMed
54.
Wigger-Alberti W, Stauss-Grabo M, Grigo K, Atiye S, Williams R, Korting HC. Efficacy of a tyrothricin-containing wound gel in an abrasive wound model for superficial wounds. Skin Pharmacol Physiol. 2013;26:52–6.CrossRefPubMed
55.
Lang C, Staiger C. Tyrothricin—An underrated agent for the treatment of bacterial skin infections and superficial wounds? Pharmazie. 2016;71:299–305.PubMed
56.
Campo JJ, Sacarlal J, Aponte JJ, Aide P, Nhabomba AJ, Dobano C, et al. Duration of vaccine efficacy against malaria: 5th year of follow-up in children vaccinated with RTS,S/AS02 in Mozambique. Vaccine. 2014;32:2209–16.CrossRefPubMed
57.
White MT, Bejon P, Olotu A, Griffin JT, Bojang K, Lusingu J, et al. A combined analysis of immunogenicity, antibody kinetics and vaccine efficacy from phase 2 trials of the RTS,S malaria vaccine. BMC Med. 2014;12:117.CrossRefPubMedPubMedCentral
58.
Boucher LE, Hopp CS, Muthinja JM, Frischknecht F, Bosch J. Discovery of Plasmodium (M)TRAP-aldolase interaction stabilizers interfering with sporozoite motility and invasion. ACS Infect Dis. 2018;4:620–34.CrossRefPubMed
59.
Zhang M, Fennell C, Ranford-Cartwright L, Sakthivel R, Gueirard P, Meister S, et al. The Plasmodium eukaryotic initiation factor-2alpha kinase IK2 controls the latency of sporozoites in the mosquito salivary glands. J Exp Med. 2010;207:1465–74.CrossRefPubMedPubMedCentral
60.
Gomes-Santos CS, Braks J, Prudencio M, Carret C, Gomes AR, Pain A, et al. Transition of Plasmodium sporozoites into liver stage-like forms is regulated by the RNA binding protein Pumilio. PLoS Pathog. 2011;7:e1002046.CrossRefPubMedPubMedCentral
61.
Moon RW, Taylor CJ, Bex C, Schepers R, Goulding D, Janse CJ, et al. A cyclic GMP signalling module that regulates gliding motility in a malaria parasite. PLoS Pathog. 2009;5:e1000599.CrossRefPubMedPubMedCentral
62.
Brochet M, Collins MO, Smith TK, Thompson E, Sebastian S, Volkmann K, et al. Phosphoinositide metabolism links cGMP-dependent protein kinase G to essential Ca(2)(+) signals at key decision points in the life cycle of malaria parasites. PLoS Biol. 2014;12:e1001806.CrossRefPubMedPubMedCentral
63.
Alam MM, Solyakov L, Bottrill AR, Flueck C, Siddiqui FA, Singh S, et al. Phosphoproteomics reveals malaria parasite Protein Kinase G as a signalling hub regulating egress and invasion. Nat Commun. 2015;6:7285.CrossRefPubMedPubMedCentral
64.
Falae A, Combe A, Amaladoss A, Carvalho T, Menard R, Bhanot P. Role of Plasmodium berghei cGMP-dependent protein kinase in late liver stage development. J Biol Chem. 2010;285:3282–8.CrossRefPubMed
65.
66.
67.
Shen B, Sibley LD. Toxoplasma aldolase is required for metabolism but dispensable for host-cell invasion. Proc Natl Acad Sci USA. 2014;111:3567–72.CrossRefPubMed
68.
Jacot D, Tosetti N, Pires I, Stock J, Graindorge A, Hung YF, et al. An apicomplexan actin-binding protein serves as a connector and lipid sensor to coordinate motility and invasion. Cell Host Microbe. 2016;20:731–43.CrossRefPubMed
69.
Stauss-Grabo M, Atiye S, Le T, Kretschmar M. Decade-long use of the antimicrobial peptide combination tyrothricin does not pose a major risk of acquired resistance with gram-positive bacteria and Candida spp. Pharmazie. 2014;69:838–41.PubMed
70.
71.
Gumila C, Ancelin ML, Delort AM, Jeminet G, Vial HJ. Characterization of the potent in vitro and in vivo antimalarial activities of ionophore compounds. Antimicrob Agents Chemother. 1997;41:523–9.PubMedPubMedCentralCrossRef
72.
D’Alessandro S, Corbett Y, Ilboudo DP, Misiano P, Dahiya N, Abay SM, et al. Salinomycin and other ionophores as a new class of antimalarial drugs with transmission-blocking activity. Antimicrob Agents Chemother. 2015;59:5135–44.CrossRefPubMedPubMedCentral
73.
Bane KS, Lepper S, Kehrer J, Sattler JM, Singer M, Reinig M, et al. The actin filament-binding protein coronin regulates motility in Plasmodium sporozoites. PLoS Pathog. 2016;12:e1005710.CrossRefPubMedPubMedCentral
74.
Douglas RG, Nandekar P, Aktories JE, Kumar H, Weber R, Sattler JM, et al. Inter-subunit interactions drive divergent dynamics in mammalian and Plasmodium actin filaments. PLoS Biol. 2018;16:e2005345.CrossRefPubMedPubMedCentral
75.
Muthinja JM, Ripp J, Kruger T, Imle A, Haraszti T, Fackler OT, et al. Tailored environments to study motile cells and pathogens. Cell Microbiol. 2018;20:e12820.CrossRef
76.
Yang X, Yousef AE. Antimicrobial peptides produced by Brevibacillus spp.: structure, classification and bioactivity: a mini review. World J Microbiol Biotechnol. 2018;34:57.CrossRefPubMed
77.
Otten-Kuipers MA, Coppens-Burkunk GW, Kronenburg NA, de Vis MA, Roelofsen B, Op den Kamp JA. Tryptophan-N-formylated gramicidin causes growth inhibition of Plasmodium falciparum by inducing potassium efflux from infected erythrocytes. Parasitol Res. 1997;83:185–92.CrossRefPubMed
78.
Otten-Kuipers MA, Franssen FF, Nieuwenhuijs H, Overdulve JP, Roelofsen B, Op den Kamp JA. Effect of tryptophan-N-formylated gramicidin on growth of Plasmodium berghei in mice. Antimicrob Agents Chemother. 1997;41:1778–82.PubMedPubMedCentralCrossRef
79.
Rautenbach M, Vlok NM, Stander M, Hoppe HC. Inhibition of malaria parasite blood stages by tyrocidines, membrane-active cyclic peptide antibiotics from Bacillus brevis. Biochim Biophys Acta. 2007;1768:1488–97.CrossRefPubMed
80.
Urry DW, Goodall MC, Glickson JD, Mayers DF. The gramicidin A transmembrane channel: characteristics of head-to-head dimerized (L, D) helices. Proc Natl Acad Sci USA. 1971;68:1907–11.CrossRefPubMed
81.
82.
Kiricsi M, Prenner EJ, Jelokhani-Niaraki M, Lewis RN, Hodges RS, McElhaney RN. The effects of ring-size analogs of the antimicrobial peptide gramicidin S on phospholipid bilayer model membranes and on the growth of Acholeplasma laidlawii B. Eur J Biochem. 2002;269:5911–20.CrossRefPubMed
83.
Stein BS, Bensch KG, Sussman HH. Complete inhibition of transferrin recycling by monensin in K562 cells. J Biol Chem. 1984;259:14762–72.PubMed
84.
Matheke ML, Fliesler SJ, Basinger SF, Holtzman E. The effects of monensin on transport of membrane components in the frog retinal photoreceptor. I. Light microscopic autoradiography and biochemical analysis. J Neurosci. 1984;4:1086–92.CrossRefPubMed
85.
Banerjee S, Argaez C. In: Topical antibiotics for infection prevention: a review of the clinical effectiveness and guidelines. Ottawa (ON); 2017.
86.
Kuchler S, Radowski MR, Blaschke T, Dathe M, Plendl J, Haag R, Schafer-Korting M, Kramer KD. Nanoparticles for skin penetration enhancement—a comparison of a dendritic core-multishell-nanotransporter and solid lipid nanoparticles. Eur J Pharm Biopharm. 2009;71:243–50.CrossRefPubMed
87.
Contri RV, Fiel LA, Alnasif N, Pohlmann AR, Guterres SS, Schafer-Korting M. Skin penetration and dermal tolerability of acrylic nanocapsules: influence of the surface charge and a chitosan gel used as vehicle. Int J Pharm. 2016;507:12–20.CrossRefPubMed
88.
Schulz R, Yamamoto K, Klossek A, Flesch R, Honzke S, Rancan F, et al. Data-based modeling of drug penetration relates human skin barrier function to the interplay of diffusivity and free-energy profiles. Proc Natl Acad Sci USA. 2017;114:3631–6.CrossRefPubMed
89.
Marren K. Dimethyl sulfoxide: an effective penetration enhancer for topical administration of NSAIDs. Phys Sportsmed. 2011;39:75–82.CrossRefPubMed
Metadata
Title
Screening for potential prophylactics targeting sporozoite motility through the skin
Authors
Ross G. Douglas
Miriam Reinig
Matthew Neale
Friedrich Frischknecht
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2018
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/s12936-018-2469-0

Other articles of this Issue 1/2018

Malaria Journal 1/2018 Go to the issue

Review

On the epidemiology of Plasmodium vivax malaria: past and present with special reference to the former USSR

Case report

Poor response to artesunate treatment in two patients with severe malaria on the Thai–Myanmar border

Research

Larvicidal activity of Zanthoxylum acanthopodium essential oil against the malaria mosquitoes, Anopheles anthropophagus and Anopheles sinensis

Research

Population genetic structure and natural selection of Plasmodium falciparum apical membrane antigen-1 in Myanmar isolates

Research

LLIN Evaluation in Uganda Project (LLINEUP): factors associated with ownership and use of long-lasting insecticidal nets in Uganda: a cross-sectional survey of 48 districts

Research

Antibody levels to recombinant VAR2CSA domains vary with Plasmodium falciparum parasitaemia, gestational age, and gravidity, but do not predict pregnancy outcomes
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits